TCB Capital Advisors Expands Strategic Advisory Board

Boutique merchant bank/advisory firm TCB Capital Advisors has grown its strategic advisory board (SAB) with the addition of leading experts in public health, diagnostics, biotech, strategic partnerships, and entrepreneurship.

The SAB now includes:

• Jason Baumgartner, a serial entrepreneur who previously founded Thrivr Health and BEKHealth and has held leadership roles at SHYFT Analytics, Quintiles (now IQVIA), and Campbell Alliance. Baumgartner earned an MBA from Duke University’s Fuqua School of Business.
• Robin Costello, who has more than 30 years of experience as a business development executive specializing in strategic partnerships in life sciences, healthcare, financial services, and technology. Her career includes pivotal roles such as director of Strategic Partnerships at SAS Institute, where she spearheaded executive engagement and drove long-term business growth. Previously, Costello was vice president of Business Development at the Council for Entrepreneurial Development, where she facilitated connections between entrepreneurs, corporates, and investors throughout the United States A dedicated relationship-builder, Costello has successfully secured and cultivated partnerships with global industry leaders and is deeply involved in economic and business development initiatives. Costello earned an MPA from Pennsylvania State University and a bachelor of arts degree in political science from the University of North Carolina at Chapel Hill.
• Greg Hamilton, the CEO of Accellix Inc. and board member of io9 Inc. who boasts more than 25 years of management experience in molecular diagnostics, manufacturing, and professional services. He has led multiple U.S. Food and Drug Administration (FDA)-cleared products, including the first FDA-approved liquid biopsy test. Hamilton earned an MBA from the University of Chicago and a bachelor of science degree in finance from Purdue University.
• Eric Mayer, president and CEO of New Day Diagnostics, who has extensive experience in biotech startups, business development, and strategic partnerships. He earned a bachelor of science degree in biochemistry from the University of North Carolina at Chapel Hill, an M.S. in microbial biotechnology, and an MBA from North Carolina State University.
• Navroze S. Mehta, the founder and CEO of Impact Medical Innovations, a company dedicated to promoting technologies that can solve major global medical unmet needs. Mehta has been a member of the Young Presidents Organization (YPO) for 20 years, is past chair of the Americas Gateway Chapter, and served as Regional Chair of the Economic Development Network. He earned an MBA from Syracuse University and a bachelor of commerce degree from Sydenham College at the University of Bombay, India.
• Kenneth A. Sorensen, Ph.D., a biotechnology entrepreneur, investor, registered patent agent, and independent research scientist (Salk Institute). He founded Array Capital Management LLC, achieving significant returns in life sciences investments. Previously, Dr. Sorensen managed the Ariane Fund and supervised the Human Genome Policy Steering body at the U.S. Patent and Trademark Office. Dr. Sorensen earned a dual bachelor of science degree in molecular and cellular biology from the University of Kansas and a Ph.D. in developmental neurobiology from the University of Arizona.
• Ted Witek (DrPH), who has decades of experience in research, development, and leadership as well as executive responsibilities as CSO and CEO across Europe and North America. He has managed some of the pharmaceutical sector’s largest strategic alliances. In 2023, he was appointed full professor at the University of Toronto, directing the school’s Doctor of Public Health Program. Dr. Witek also is a recipient of the 2024 Yale School of Public Health Distinguished Alumni Award for his leadership in pubic health as an outstanding teacher, researcher, and practitioner. He earned a Doctor of Public Health (DrPH) degree from Columbia University, an MPH from Yale University, and an MBA from Henley Management College in London. Dr. Witek earned his ICD.D designation from The Rotman School of Management at the University of Toronto and The Institute of Corporate Directors in 2019.
• Greg Wujek, the chief commercial officer at Actum Pharma. He has more than 30 years of experience in the biopharmaceutical industry, including positions of increasing responsibility at several companies. He was formerly CEO of Castle Creek Pharmaceuticals and was responsible for several successful product launches and strategic acquisitions throughout his career. Wujek earned a bachelor of science degree in political science from Illinois State University.

Establishing the SAB provides TCB and its clients with strategic counsel, operational expertise, and access to a powerful network of decision makers and centers of influence across both Wall Street and industry verticals. Between the SAB and TCB’s principals, the firm now brings decades of experience in the healthcare and life sciences sectors, working with companies that range from early-stage ventures to FORTUNE 500 companies, and collectively has successfully completed numerous exits for companies they founded or led.

“With the expansion of our Strategic Advisory Board, we can provide clients unique access to several leading experts from across the healthcare and life sciences worlds, adding significant value to respective capital markets and other growth initiatives,” TCB President/Managing Director Sam Libby said. “Securing such prestigious executives as members of our team and platform is a true testament to the continued success of TCB and the strong reputation that we have established since our founding in 2022. We are grateful for the support of these industry titans and look forward to strengthening client relationships and achieving impactful results together for years to come.”

Working as an extension of TCB’s core team, the SAB offers key insights into emerging and established markets, helps address evolving client needs, and advances TCB’s partner initiatives. This includes supporting Project Felizia, a collaborative effort between TCB and Activated Concepts aimed at addressing critical gaps in menopause care by leveraging advanced analytics and AI to provide personalized, evidence-based solutions.

TCB Capital Advisors is a boutique merchant bank and advisory firm focused on the healthcare and life sciences sectors. The firm specializes in advising clients with buying, selling, investment, and growth strategies, leveraging decades of combined Wall Street and industry experience. TCB Capital Advisors offers a tailored approach to clients, focusing on transaction advisory, corporate development, revenue growth, and post-transaction integration, working with clients across venture, growth, and middle-market verticals. Founded in 2023 by former members of the healthcare team at Piper Sandler, TCB Capital Advisors is headquartered in The Woodlands, Texas, with offices/team members based in New York, North Carolina, and Tennessee. Securities are offered through Finalis Securities LLC.